Stockscreener 앱 받기
16.92
2.73%
0.45
시간 외 거래:
16.89
-0.03
-0.18%
전일 마감가:
$16.47
열려 있는:
$16.6
하루 거래량:
880.20K
Relative Volume:
0.71
시가총액:
$1.87B
수익:
$-665.00K
순이익/손실:
$-144.74M
주가수익비율:
-10.90
EPS:
-1.5527
순현금흐름:
$-123.48M
1주 성능:
+4.00%
1개월 성능:
+20.94%
6개월 성능:
+19.24%
1년 성능:
+333.85%
1일 변동 폭
$16.46
$17.33
1주일 범위
$16.05
$17.36
52주 변동 폭
$3.79
$17.49
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
명칭
Amylyx Pharmaceuticals Inc
전화
617-682-0917
주소
55 CAMBRIDGE PARKWAY, CAMBRIDGE
Compare AMLX vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
16.92 | 1.81B | -665.00K | -144.74M | -123.48M | -1.5527 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
121.11 | 49.56B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.86B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.77 | 35.89B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
578.54 | 25.06B | 3.18B | 1.33B | 1.04B | 27.90 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-03 | 개시 | Stifel | Buy |
| 2025-07-10 | 재개 | Goldman | Buy |
| 2025-06-24 | 개시 | Guggenheim | Buy |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2025-05-30 | 개시 | TD Cowen | Buy |
| 2025-04-07 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-11-18 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-03-18 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-03-11 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-03 | 개시 | Robert W. Baird | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-07-24 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2023-01-05 | 개시 | BofA Securities | Buy |
| 2022-05-25 | 개시 | Citigroup | Buy |
| 2022-04-01 | 다운그레이드 | Goldman | Buy → Neutral |
모두보기
Amylyx Pharmaceuticals Inc 주식(AMLX)의 최신 뉴스
Bull Run: What is Amylyx Pharmaceuticals Incs book value per share2026 Dividend Review & Daily Profit Maximizing Tips - baoquankhu1.vn
Amylyx Pharmaceuticals, Inc. (AMLX) stock price, news, quote and history - Yahoo Finance Singapore
Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Finviz
Layoff Watch: Is Amylyx Pharmaceuticals Inc stock a smart retirement pick2026 Patterns & AI Powered Trade Plan Recommendations - baoquankhu1.vn
AMLX SEC FilingsAmylyx Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference - BioSpace
Buy Rating on Amylyx: De-Risked Avexitide Phase III Study and Significant PBH Market Opportunity Support 2027 Launch Potential - TipRanks
A Look At Amylyx Pharmaceuticals (AMLX) Valuation As Avexitide Hits A Key Phase 3 LUCIDITY Milestone - Sahm
Amylyx Pharmaceuticals Inc (AMLX) Shares Up 6.66% on Apr 6 - GuruFocus
Amylyx Pharmaceuticals Shares Rise 6.9% on Positive News - National Today
Amylyx Pharmaceuticals (NASDAQ:AMLX) Shares Up 6.9%What's Next? - MarketBeat
Amylyx (AMLX) -7.8%: Earnings Show $0 Revenue, Shelf Filing Adds Dilution Fear - Trefis
Amylyx Pharmaceuticals Inc (AMLX) Shares Up 3.52% on Apr 2 - gurufocus.com
AMLX Stock Price, Quote & Chart | AMYLYX PHARMACEUTICALS INC (NASDAQ:AMLX) - ChartMill
The Bull Case For Amylyx Pharmaceuticals (AMLX) Could Change Following LUCIDITY Trial Enrollment Milestone Completion - Sahm
Amylyx Pharmaceuticals (NASDAQ:AMLX) Shares Up 9%Still a Buy? - MarketBeat
Amylyx Pharmaceuticals (AMLX) Winds Up Avexitide Phase 3 Lucidity Trial Enrollment - Insider Monkey
Buyback Watch: Is Amylyx Pharmaceuticals Inc stock a smart retirement pick2026 Trade Ideas & Smart Allocation Stock Tips - baoquankhu1.vn
A Look At Amylyx Pharmaceuticals (AMLX) Valuation After LUCIDITY Phase 3 Trial Reaches Full Enrollment - simplywall.st
Is LUCIDITY Trial Completion in Post-Bariatric Hypoglycemia Altering The Investment Case For Amylyx Pharmaceuticals (AMLX)? - Yahoo Finance
Vanguard realigns holdings; AMLX ownership reported at 0% (Vanguard) - Stock Titan
Market Recap: Is Amylyx Pharmaceuticals Inc benefiting from interest rate changesEarnings Recap Summary & Fast Gain Swing Alerts - baoquankhu1.vn
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
HC Wainwright Reaffirms Buy Rating for Amylyx Pharmaceuticals (NASDAQ:AMLX) - MarketBeat
H.C. Wainwright reiterates Amylyx stock rating on trial progress By Investing.com - za.investing.com
H.C. Wainwright reiterates Amylyx stock rating on trial progress - Investing.com
Amylyx Pharmaceuticals Advances Novel Therapies for Rare Diseases: Avexitide, AMX0035, and AMX0114 Show Promise in Clinical Trials for PBH, Wolfram Syndrome, and ALS - Minichart
Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia - BioSpace
Amylyx Highlights Pipeline Progress in Updated Corporate Presentation - TipRanks
Amylyx Pharmaceuticals completes enrollment in Phase 3 LUCIDITY trial for PBH - Traders Union
Amylyx updates presentation: LUCIDITY and LUMINA enrollment complete; LUCIDITY topline due Q3 2026 - TradingView
Amylyx (NASDAQ: AMLX) details avexitide Phase 3 timing and cash runway into 2028 - Stock Titan
Amylyx Pharmaceuticals Q4 2025 earnings preview - MSN
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - Barchart
Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
Amylyx Pharmaceuticals Inc (AMLX) Shares Gap Down to $13.78 on M - GuruFocus
Maven Securities LTD Makes New $951,000 Investment in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Fund Flows: Is Amylyx Pharmaceuticals Inc stock a smart retirement pickPortfolio Gains Report & Weekly Sector Rotation Insights - baoquankhu1.vn
Amylyx shares slip despite Q4 beat as investors focus on trial timeline - MSN
Amylyx Pharmaceuticals expands team to address urgent healthcare challenges - Traders Union
How Investors May Respond To Amylyx Pharmaceuticals (AMLX) Narrowed 2025 Losses And Expanded Shelf Capacity - simplywall.st
Buy Rating on Amylyx Pharmaceuticals Driven by Avexitide’s Commercial Potential and De-Risked Phase III PBH Program - TipRanks
First Light Asset Management LLC Purchases Shares of 3,355,882 Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Amylyx Pharmaceuticals, Inc. $AMLX Shares Sold by Boxer Capital Management LLC - MarketBeat
Amylyx Pharmaceuticals Inc (AMLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.06%
1.05%
자본화:
|
볼륨(24시간):